ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients by Fehm, Tanja et al.
Open Access
Available online http://breast-cancer-research.com/content/10/5/R76
Page 1 of 8
(page number not for citation purposes)
Vol 10 No 5 Research article
ERalpha-status of disseminated tumour cells in bone marrow of 
primary breast cancer patients
Tanja Fehm1, Natalia Krawczyk1, Erich-Franz Solomayer1, Graziella Becker-Pergola1, Silke Dürr-
Störzer1, Hans Neubauer1, Harald Seeger1, Annette Staebler2, Diethelm Wallwiener1 and 
Sven Becker1
1Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, D-72076 Tuebingen, Germany
2Department of Pathology, University of Tuebingen, Liebermeisterstrasse 8, D-72076 Tuebingen, Germany
Corresponding author: Tanja Fehm, tanja.fehm@t-online.de
Received: 1 Jul 2008 Revisions requested: 14 Aug 2008 Revisions received: 11 Sep 2008 Accepted: 15 Sep 2008 Published: 15 Sep 2008
Breast Cancer Research 2008, 10:R76 (doi:10.1186/bcr2143)
This article is online at: http://breast-cancer-research.com/content/10/5/R76
© 2008 Fehm et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Isolated disseminated tumour cells (DTC) are
regarded as surrogate markers for minimal residual disease in
breast cancer. Characterisation of these cells could help
understand the known limitations of adjuvant therapy. Of
particular interest is their oestrogen-receptor (ER) status
because endocrine adjuvant therapy remains a cornerstone of
breast cancer treatment.
Methods Bone marrow (BM) aspirates from 254 patients with
primary breast cancer were included in this study. A double
immunofluorescence staining procedure was established for the
identification of cytokeratin (CK) positive/Erα-positive cells. ERα
status of the primary tumour was assessed
immunohistochemically using the same antibody against ERα.
Results In 107 of 254 (42%) breast cancer patients, CK-
positive cells could be detected in the BM. More than one DTC
in the BM was observed in 38 of the 107 patients. The number
of detected cells ranged between 1 and 55 cells per 2 × 106
mononuclear cells. DTCs demonstrated ERα positivity in 12%
of the patients. The ERα expression was heterogeneous in 10 of
the 38 (26%) patients with more than one DTC. The
concordance rate of ERα status between primary tumour and
DTC was 28%. Only 12 of 88 patients with ERα-positive
tumours also had ERα-positive DTCs.
Conclusions Primary tumours and DTCs displayed a
concordant ERα status in only 28% of cases. Most of the DTCs
were ERα negative despite the presence of an ERα-positive
primary tumour. These findings further underline the distinct
nature of DTCs and may explain the failure rates seen in
conventional endocrine adjuvant therapy.
Introduction
Tumour cell dissemination is a common phenomenon in breast
cancer where isolated disseminated cells can be detected in
up to 40% of patients at the time of primary diagnosis [1-3].
Based on the pooled analysis of the bone marrow (BM)
micrometastasis group, disseminated tumour cells (DTC) are
a surrogate marker of minimal residual disease. Their presence
is associated with a poor prognosis [4]. With their prognostic
significance clearly demonstrated, efforts have been made to
further characterise these cells using pheno- and genotyping
techniques. Studies have shown that the persistence of DTCs
in the BM of patients with primary breast cancer after conven-
tional adjuvant therapy is associated with a poor prognosis [5-
7].
More detailed knowledge about their cellular and molecular
characteristics could help define a targeted secondary adju-
vant therapy in patients with primary breast cancer who have
undergone conventional adjuvant therapy. It has already been
shown that about 40% of DTCs express human epidermal
growth factor receptor 2 (HER2) and that in some patients
with recurrent breast cancer their HER2 status may differ from
BM: bone marrow; BSA: bovine serum albumin; CK: cytokeratin; DAB: 3,3' diaminobenzidine; DAPI: 4'6-diamidino-2-phenylindole; DTC: dissemi-
nated tumour cells; ER: oestrogen receptor; FITC: fluorescein isothiocyanate; HER2: human epidermal growth factor receptor 2; MHC: major histo-
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that of the primary tumour [8]. Since the most widely used form
of targeted therapy for breast cancer remains anti-oestrogen
endocrine therapy, it is important to know if the ERα status of
DTCs corresponds to the ERα status of the primary tumour,
particularly in view of the 15 to 20% relapse rate in early stage
ERα-positive tumours despite adjuvant endocrine therapy [9].
Furthermore, while ERα-negative tumours are not considered
candidates for endocrine therapy, the ERα status of DTCs
may differ from the primary tumour. The goal of this study was
to determine the ERα status of DTCs in BM of breast cancer
patients, and to compare the ERα status of DTCs and the cor-
responding primary tumours.
Materials and methods
Collection and analysis of bone marrow
Prior to any therapy, between 10 and 20 ml of bone marrow
were aspirated from the anterior iliac crest of 254 primary
breast cancer patients undergoing surgical treatment from
2005 to 2007 at the Department of Gynecology and Obstet-
rics, University Hospital Tuebingen, Germany.
The characteristics of the patients are shown in Table 1. All
specimens were obtained after written informed consent was
given and were collected using protocols approved by the
institutional review board (114/2006A). Tumour cell isolation
and detection was performed based on the recommendations
for standardised tumour cell detection [10]. BM samples were
separated by density centrifugation over Ficoll with a density
of 1.077 g/ml (Biochrom, Germany). If necessary red blood
cells were lysed with lysis buffer (155 mM NH4Cl, 10 mM
KHC03, 0.1 mM EDTA pH 7.2). Using a cytocentrifuge (Het-
tich, Tuttlingen, Germany), 106 mononuclear cells were spun
onto a glass slide. The slides were air-dried overnight at room
temperature. For detection and characterisation of DTCs,
slides were fixed in a 0.5% neutral buffered formalin solution
for 10 minutes. Control cytospins with ERα-positive MCF-7
cells were prepared, stored and fixed in the same way to
ensure that ERα negativity of a patient's sample was not due
to a handling error. Two slides per patient was analysed for the
presence of DTCs (2 × 106 cells per patient).
Optimising the ERα staining protocol
For establishing the ERα staining procedure, preparations of
breast cancer cell lines MCF-7 and SKBR3 mixed with either
BM or peripheral blood mononuclear cells (PBMCs) from a
healthy volunteer were used (Figure 1). To optimise the stain-
ing procedure, all relevant parameters of the protocol were
evaluated as follows: types of primary ERα antibodies used
were monoclonal mouse antibodies (NCL-L-ER-6F11, Novo-
castra Laboratories, UK), polyclonal rabbit antibodies (H-184,
Santa Cruz Biotechnology, Inc., CA) and monoclonal rabbit
antibodies (SP1, Lab Vision, CA); antibody dilutions used
were 1:200, 1:100, 1:50 and 1:25 made with DAKO Antibody
Diluent (1% BSA in PBS, 0.1% Tween 20); incubation times
for primary and secondary antibodies were 30, 45 and 60 min-
utes; selection of secondary antibodies was with Tex-Red
labelled horse anti-mouse AB (Vector Laboratories, Inc., CA),
Tex-red labelled goat anti-rabbit AB (CB 11, Biogenex, CA)
and Alexa Fluor 594 labelled goat anti rabbit AB (Molecular
Probes, Invitrogen, CA); cell fixation was 10 minutes of ace-
tone at 4°C, 100% ethanol for 10 minutes or 0.5% neutral
buffered formalin solution for 10 minutes, all three fixations at
room temperature. The optimal ERα staining (low background,
strong nuclear staining, no cytoplasmic staining) was deter-
mined to be as indicated below.
Table 1
Clinical data of patients
n = 254 BM positive (%) p-value*
Total 254 107 (42)
Menopausal status
Premenopausal 79 33 (42) 0.94
Postmenopausal 175 74 (42)
Tumour size
pT1 148 60 (41) 0.77
pT2-4 103 46 (45)
Nodal status
Node negative 149 62 (42) 0.88
Node positive 101 43 (43)
Histology
Ductal 177 74 (42) 0.12
Lobular 57 21 (37)
Others 17 11 (65)
Grading
I to II 217 91 (42) 0.85
III 32 14 (44)
ER status
Negative 42 19 (45) 0.83
Positive 208 88 (42)
PR status
Negative 69 26 (38) 0.39
Positive 181 79 (44)
HER2
Negative (0/+1) 211 94 (45) 0.08
Positive (+2/+3) 32 9 (28)
* by Chi-squared test. BM = bone marrow; ER = oestrogen receptor; 
HER2 = human epidermal growth factor receptor 2; PR = 
progesterone receptor.Available online http://breast-cancer-research.com/content/10/5/R76
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Immunofluorescence staining of ERα-receptor
After an initial washing step with PBS (Sigma, Munich, Ger-
many), cells were blocked for 30 minutes with normal goat
serum (Dako, Glostrup, Denmark) at a 1:10 dilution. The auto-
mated double immunofluorescence staining procedure was
performed on the DAKO Autostainer using the monoclonal
rabbit ERα-antibody SP1 (dilution 1:25, Lab Vision, Fremont,
CA, USA) for 60 minutes and secondary detection with a goat
anti-rabbit antibody, labelled with Alexa Fluor 594 (1:100, Inv-
itrogen Molecular Probes, Carlsbad, CA, USA) for 30 minutes.
Cytospins were then incubated with a pan-cytokeratin (CK)
antibody (C11) directly conjugated to fluorescein isothiocy-
anate (FITC) (1:100, Sigma, Munich, Germany) for 30 min-
utes. This monoclonal antibody recognises human CKs 4, 5, 6,
8, 10, 13 and 18. Counterstaining was performed with 4'6-dia-
midino-2-phenylindole (DAPI) in mounting media (Vector Lab-
oratories, Burlingame, CA, USA). Preparations of the breast
cancer cell line MCF-7 mixed with PBMCs from a healthy vol-
unteer served as a positive control for CK and ERα staining.
ERα negative control slides of SKBR-3/PBMC mixtures were
also included with each batch of samples. Cytospins of
PBMCs with no added tumour cells served as a negative con-
trol for both.
Fluorescence microscopy
Slides were manually analysed for the presence of tumour
cells using a computerised fluorescence microscope Axiophot
(×40 oil immersion objectives, Carl Zeiss Micro Imaging
GmbH, Göttingen, Germany). To screen for ERα-positive
tumour cells, a single-pass filter for individual fluorochromes,
FITC, Texas Red or DAPI, and a dual-pass filter for FITC/Texas
Red were used. Criteria for evaluation of immunostained cells
were based on the criteria of the International Society of
Hematotherapy and Graft Engineering Working group for
standardisation of tumour cell detection and the consensus
statements [10,11]. Criteria for ERα positivity were either
moderate or intense staining of the entire nucleus. Slides were
evaluated by two, or in doubtful cases three, independent
investigators (TF, NK and ES).
Immunohistochemical staining of the primary tumour
Immunohistochemical analysis was performed either on core
biopsies or surgical resection specimens. The tissue was fixed
in 4.5% buffered formalin (pH 7.0) and embedded in paraffin.
Immunohistochemical staining was performed on 3 to 5 μm
thick sections using a commercially available ABC kit
(Vectastain, Vector Laboratories, Burlingame, CA, USA). The
ERα antibody (clone SP1) was diluted 1:200 in Tris-HCl (pH
7.5) and applied according to the manufacturer's instruction
(DCS, Hamburg, Germany). 3,3'diaminobenzidine (DAB) was
used as a chromogen. Finally, the slides were counterstained
with haematoxylin and mounted for examination. For assess-
ment of the ERα status, the percentage of cells with nuclear
reactivity (score 0: none, 1: > 10%, 2: 10 to 50%, 3: 51 to
80%, 4: > 80%) and the intensity of ER staining (score 0:
none, 1: weak, 2: moderate, 3: strong) was determined. ERα
expression was scored semi-quantitatively using the Rem-
mele-score (score nuclear staining × score intensity of ER
staining). Tumours with a score of 2 or more were considered
ERα positive.
Statistical analysis
A chi-squared test or Fisher's exact test was used to evaluate
the relation between ERα-positive DTCs and clinicopatholog-
ical factors. Statistical analysis was performed by SPSS, ver-
sion 11.5 (SPSS Inc., Chicago, IL, USA). p < 0.05 was
considered statistically significant.
Results
Patients' charateristics
A total of 254 patients were included in the study. Clinical data
are shown in detail in Table 1. Of patients, 82% had ERα-pos-
itive primary tumours and DTCs were observed in 107 (42%)
of them. Figure 2 shows the cytomorphology and immunophe-
notype of a representative DTC of a patient with breast cancer.
As can be seen, the nuclear to cytoplasmic ratio is high, the
Figure 1
Oestogen receptor (ER) α staining of MCF-7 (positive control) and  SKBR3 (negative control) breast cancer cells spiked in bone marrow Oestogen receptor (ER) α staining of MCF-7 (positive control) and 
SKBR3 (negative control) breast cancer cells spiked in bone marrow. 
A: MCF-7 cancer cells as positive control for ERα-staining. B: SKBR3 
cancer cells as negative control ERα-staining.
Figure 2
Typical cytomorphology (nuclear size clearly enlarged, high nuclear to  cytoplasmic ratio) and immunophenotype (irregular cytoplasmic stain- ing for cytokeratin, cytokeratin filaments can be seen) of a representa- tive disseminated tumour cell from a breast cancer patient Typical cytomorphology (nuclear size clearly enlarged, high nuclear to 
cytoplasmic ratio) and immunophenotype (irregular cytoplasmic stain-
ing for cytokeratin, cytokeratin filaments can be seen) of a representa-
tive disseminated tumour cell from a breast cancer patient. The tumour 
cell is stained with an anti-cytokeratin-fluorescein isothiocyanate 
(green) (×40 oil immersion objective).Breast Cancer Research    Vol 10 No 5    Fehm et al.
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nucleus has irregularities and the CK stains the cytoplasm at
the periphery of the cell causing a ring-like appearance. These
are all accepted morphological criteria for malignant cells. The
number of DTCs ranged from 1 to 55 cells/patient (2 × 106
mononuclear cells). In 38 of the 107 (35%) BM-positive
patients, more than one DTC could be detected. No correla-
tion was observed between positive BM status and any of the
established prognostic markers including the ERα status of
the primary tumour (Table 1).
ERα expression in disseminated tumour cells
ERα status of DTCs was simultaneously evaluated using a
double immunofluorescence staining procedure. The majority
of patients (88%) had ERα-negative tumour cells in BM (Table
2). ERα-positive tumour cells could only be detected in 13 of
107 (12%) patients with BM involvement. ERα-positive but
CK-negative cells were not observed. Figure 3 shows ERα-
positive tumour cells from different patients. As can be seen,
the nuclei are strongly stained with the ER antibody.
Of the 107 patients, 38 had more than one DTC in the BM. Of
Table 2
Correlation between ERα status of primary tumour and disseminated tumour cells
ERα status DTC Total (%)
ERα negative (%) ERα positive (%)
Tumour ERα negative (%) 18 (17) 1 (1) 19 (18)
ERα positive (%) 76 (71) 12 (11) 88 (82)
Total (%) 94 (88) 13 (12) 107 (100)*
*p = 0.8 (chi-squared-test). ER = oestrogen receptor; DTC = disseminated tumour cells.
Figure 3
Immunophenotyping of disseminated tumour cells from patients with primary breast cancer Immunophenotyping of disseminated tumour cells from patients with primary breast cancer. The tumour cells were stained with an anti-cytokeratin-
fluorescein isothiocyanate (green) and anti-oestrogen receptor (ER)α detected by a secondary Alexa Fluor 594 labelled goat anti-rabbit antibody 
(red). Nuclei are stained blue with 4'6-diamidino-2-phenylindole (DAPI) (×40 oil immersion objective). A-F: Breast cancer patients with ERα-positive 
disseminated tumour cells. G-H: Clusters of ERα-positive disseminated tumour cells. I: Cluster of ERα-positive and ERα-negative tumour cells.Available online http://breast-cancer-research.com/content/10/5/R76
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these 38 patients, 28 had only ERα-negative tumour cells
(Table 3). Heterogeneity of ERα expression could be detected
in the remaining 10 (26%) patients (Figure 3i).
Comparison of ERα expression between primary tumour 
and disseminated tumour cells
The ERα status of the primary tumour could be determined in
all 107 patients with detectable DTCs in the BM. ERα positiv-
ity of the primary tumour was demonstrated in 88 (82%) of
these patients. The concordance rate between ERα status of
DTCs and primary tumour was 28%. Only 12 of the 88 (14%)
patients with ERα-positive primary tumour had ERα-positive
DTCs in the BM. In contrast, 18 of 19 (95%) patients with
ERα-negative primary tumours also had ERα-negative DTCs
(Table 2). The extent of ERα expression (negative, low, moder-
ate or strong) of the primary tumour was not correlated to the
ERα status of DTCs. The comparison of ERα expression
between primary tumours and DTCs is summarised in Tables
2 and 3.
Discussion
Evaluation of ERα status of the primary tumour by immunohis-
tochemistry has been part of routine clinical practice for many
years and currently determines patient eligibility for adjuvant
endocrine therapy. The assumption is that DTCs will share
most characteristics with the primary tumour.
However, an increasing number of publications indicate a
more complex relation between the primary tumour and DTCs,
with considerable discrepancies noted at the genomic level
[12,13]. Supporting this evidence at the phenotypic level are
studies looking at HER2 status differences between primary
tumours and isolated DTCs [8,14,15].
Similarly, the ERα status of DTCs could be completely differ-
ent to that of the primary tumour which on the one hand (ERα-
negative primary tumour, ERα-positive DTCs) could increase
the number of patients eligible for endocrine therapy and on
the other hand (ERα-positive primary tumour, ERα-negative
DTCs) could explain why endocrine therapy fails in a subset of
hormone receptor-positive patients.
Looking at a large patient group, our data confirms findings of
previous, smaller studies, indicating that the ERα status of the
primary tumour does not necessarily reflect the ERα status of
minimal residual disease (Table 4). In an observational study
looking at 17 primary tumours and their corresponding DTCs,
Ditsch et al. found that only two of 11 patients with ERα-pos-
itive primary tumours (18%) had ERα-positive DTCs [16].
Reuben et al. investigated the ERα status of circulating tumour
cells in metastatic breast cancer patients and their corre-
sponding primary tumours: fourteen of 16 patients (88%) had
ERα-positive primary tumours, but only three patients had
ERα-positive circulating tumour cells [17]. Our results confirm
the conclusions that DTCs do not reflect the ERα status of the
corresponding primary tumour and a majority of DTCs tend to
be ERα negative.
As mentioned above, these discrepancies between DTCs and
the primary tumour are not confined to ERα-expression: Solo-
mayer et al. compared the HER2 status of DTC and primary
tumour in 137 cases [8] and found that DTCs were more likely
to express HER2 than the primary tumour. Meng et al. reported
HER2-positive circulating tumour cells in nine of 24 (38%)
patients with recurrent breast cancer who had HER2-negative
tumours [15]. It has been suggested that the high rate of
HER2-positive DTCs reflects on their potentially more aggres-
sive phenotype. Other studies looking at markers such as
major histocompatibility complex (MHC) III and Ki-76 have
reported similar discrepancies [18,19].
Different hypotheses need to be discussed with regard to our
findings. One possible explanation is the clonal heterogeneity
of the primary tumour: ERα-negative cells could be more likely
to disseminate, corresponding to the worse prognosis of pre-
dominantly ERα negative tumours and – inversely – to the
demonstrated decreased invasiveness and metastatic poten-
tial of ERα-expressing breast cancer cells [20,21]. MCF-7
cells, established from a pleural effusion, express ERα and are
oestrogen-responsive breast cancer cells. MCF-7 cells do not
form metastases in nude mice unless oestrogen supplementa-
tion is provided [22-24]. MDA-MB-231 cells were also estab-
lished from a pleural effusion; however, these cells are ERα-
negative and highly invasive. Intravenous injection of MDA-
Table 3
Correlation between ERα status of primary tumour and heterogeneity of ERα expression in patients with more than one 
disseminated tumour cell (DTC).
ERα status DTC Total (%)
ERα + (%) ERα – (%) ERα + (%) & - (%)
Tumour ERα – (%) 0 7 (18) 0 7 (18)
ERα + (%) 0 21 (55) 10 (26) 31 (82)
Total (%) 0 28 (74) 10 (26) 38 (100)
*p = 0.3 (Fisher-exact-test, two-sided). ER = oestrogen receptor.; + = positive; - = negative.Breast Cancer Research    Vol 10 No 5    Fehm et al.
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MB-231 cells into the tail vein of nude mice produces tumours
[24]. Furthermore, it is well known that about 20 to 30% of
patients with ERα-positive primary tumours develop ERα-neg-
ative metastatic diseases [25-28].
One interesting hypothesis currently under discussion is the
theory that some or all DTCs, the presumed precursor cells of
systemic metastatic disease, are in fact cancer stem cells. As
recently published, this theory states that tumour growth and
formation of secondary tumours can be traced to a small sub-
population of tumour cells, so called cancer stem cells
[29,30]. First, most DTCs do not respond to cytotoxic therapy
because they are not proliferating and persist over many years
in BM. This is also true for tumour stem cells. Secondly, it was
also demonstrated that most DTCs in BM were CD44 positive
and CD24 low/negative [31]. The CD44-/CD 24-/low pheno-
type represents a minor population within primary tumours that
is associated with self-renewal and tumourigenic potential. In
addition, it has been shown that the CD44+/CD24- pheno-
types correlated with a higher prevalence of metastases [32].
As breast cancer stem cells have been shown to be generally
ERα negative, DTCs with an ERα-negative phenotype despite
an ERα-positive primary tumour would agree with the cancer
stem cell theory [33,34].
Conclusion
The phenotypic discrepancies between DTCs and their corre-
sponding primary tumours have the potential to increase our
understanding of why treatments are successful in some, but
not in other patients, paving the way towards more individual-
ised forms of treatment. The target of adjuvant therapy is the
eradication of minimal residual disease. In order to optimise
treatment strategies, the phenotypic properties of DTCs – the
surrogate marker of minimal residual disease – should be
taken into account in addition to characterisation of the pri-
mary tumour. Already, the available studies looking at pheno-
typic properties of DTCs have often found them to be non-
proliferative, ERα negative and HER2 positive [8,16,28]. For
these patients, expanded treatment with HER2-specific thera-
pies (e.g. trastuzumab and lapatinib) could prove especially
beneficial. To further clarify these questions, the next step
should be a more generalised and systematic characterisation
of DTC-status before and after standard adjuvant therapy for
all patients.
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